LCTX Stock News & Catalysts – Lineage Cell Therapeutics

FEATURED

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today announced that it

Summary

Nov 5, 2026, 8:00 AM ·Business Wire

RECENT

Lineage Provides Update on ReSonance® Program for Hearing Loss

Advanced Collaboration with WDI for ReSonance (ANP1) Program Into Second Year: All Preclinical Development Activities Planned For Year 1 of Collaboration Successfully AchievedDanish Medicines Agency (DKMA) Meeting

Oct 29, 2026, 8:00 AM ·Business Wire

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

U.S. Patent No. 12,692,476 Has an Expected Expiration Date of June 9, 2043 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off

Sep 8, 2026, 8:00 AM ·Business Wire

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program

Aug 6, 2026, 4:01 PM ·Business Wire

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today

Jul 30, 2026, 8:00 AM ·Business Wire

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the

Jul 13, 2026, 8:00 AM ·Business Wire

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that

Jul 6, 2026, 8:00 AM ·Business Wire

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary -

May 20, 2026, 9:50 AM ·PRNewswire

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with

May 12, 2026, 4:01 PM ·Business Wire

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

May 5, 2026, 8:00 AM ·Business Wire

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial

May 4, 2026, 8:00 AM ·Business Wire

Lineage Announces Formation of Scientific Advisory Board

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the

Apr 13, 2026, 8:00 AM ·Business Wire

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB:AVAI), Lineage Cell

Apr 10, 2026, 9:55 AM ·PRNewswire

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted

Mar 24, 2026, 8:00 AM ·Business Wire

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 18, 2026 /CNW/ -- Equity-Insider.com -- There is a key "master" protein in your body called α-Klotho. You've probably never heard of it. But the

Mar 18, 2026, 10:00 AM ·PRNewswire

Lineage Cell Therapeutics, Inc. LCTX · News